Ken Griffin Omeros Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.54 - $5.47 $33,630 - $51,965	-9,500 Reduced 15.18%	53,100 $210,000
Q2 2024 Aug 14, 2024	BUY	$3.04 - $4.23 $101,232 - $140,859	33,300 Added 113.65%	62,600 $254,000
Q1 2024 May 15, 2024	SELL	$2.88 - $4.89 $170,496 - $289,488	-59,200 Reduced 66.89%	29,300 $101,000
Q4 2023 Feb 14, 2024	SELL	$1.08 - $3.63 $49,248 - $165,528	-45,600 Reduced 34.0%	88,500 $289,000
Q3 2023 Nov 14, 2023	BUY	$2.81 - $5.69 $35,406 - $71,694	12,600 Added 10.37%	134,100 $391,000
Q2 2023 Aug 14, 2023	BUY	$4.45 - $7.57 $56,515 - $96,139	12,700 Added 11.67%	121,500 $660,000
Q1 2023 May 15, 2023	SELL	$2.48 - $5.22 $233,616 - $491,724	-94,200 Reduced 46.4%	108,800 $505,000
Q4 2022 Feb 14, 2023	BUY	$1.75 - $3.96 $21,525 - $48,708	12,300 Added 6.45%	203,000 $458,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $7.46 $124,836 - $301,384	-40,400 Reduced 17.48%	190,700 $601,000

120

25.6M

228K

630K

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $747M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.